Back to news

Eli Lilly Climbs as Fresh Drug Data and Bullish Analyst Action Support Shares

Investivoq PriceTracker

Eli Lilly and Company (LLY) is up 3.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a combination of recent positive pipeline updates and supportive Wall Street sentiment rather than one single headline. Investors have had several fresh reasons to stay constructive, including new obesity and diabetes data, a recent insulin approval, and a price-target increase from an analyst on October 7, 2026.

Details:

  • Lilly disclosed detailed Phase 3 results for oral GLP-1 drug Foundayo on September 30, highlighting cardiovascular safety along with sustained A1C and weight-loss benefits in adults with type 2 diabetes.
  • On October 1, Lilly released additional analyses indicating Foundayo was linked with meaningful reductions in predicted long-term risk for type 2 diabetes and cardiovascular disease in people with obesity or overweight.
  • Lilly also announced a recent FDA approval for Onswik, a once-weekly basal insulin for adults with type 2 diabetes, adding another regulatory win to the company’s diabetes portfolio.
  • Separately, an analyst note published October 7 showed a maintained bullish rating and a higher price target, which may have added momentum to an already favorable setup.

    • Sources:

    Eli Lilly and Company, SEC, Light Horse Securities

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $LLY Insider Trading Activity

    LLY Insider Trades

    $LLY insiders have traded $LLY stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.

    Here’s a breakdown of recent trading of $LLY stock by insiders over the last 6 months:

    • PATRIK JONSSON (EVP & President, LLY Int'l) sold 6,500 shares for an estimated $7,638,149
    • ANAT HAKIM (EVP, GC & Secretary) sold 5,000 shares for an estimated $5,950,000
    • ILYA YUFFA (EVP&Pres, LLY USA&Global Capab) sold 2,500 shares for an estimated $2,876,925
    • DONALD A ZAKROWSKI (SVP, Finance, & CAO) sold 2,000 shares for an estimated $2,370,020

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    Investivoq Alerts
    Receive LLY Data Alerts
    Get market-moving data, filings, and signals for LLY in real time.
    Sign Up

    $LLY Hedge Fund Activity

    We have seen 2,509 institutional investors add shares of $LLY stock to their portfolio, and 1,569 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • JPMORGAN CHASE & CO added 12,598,524 shares (+inf%) to their portfolio in Q2 2026, for an estimated $15,111,047,641
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 6,001,955 shares (+inf%) to their portfolio in Q2 2026, for an estimated $7,198,924,885
    • CAPITAL RESEARCH GLOBAL INVESTORS removed 3,759,507 shares (-15.3%) from their portfolio in Q2 2026, for an estimated $4,509,265,481
    • WELLINGTON MANAGEMENT GROUP LLP removed 2,428,108 shares (-18.1%) from their portfolio in Q2 2026, for an estimated $2,912,345,578
    • FMR LLC added 2,121,444 shares (+8.1%) to their portfolio in Q2 2026, for an estimated $2,544,523,576
    • LILLY ENDOWMENT INC removed 1,520,000 shares (-1.7%) from their portfolio in Q2 2026, for an estimated $1,823,133,600
    • SG AMERICAS SECURITIES, LLC added 1,331,427 shares (+204.1%) to their portfolio in Q2 2026, for an estimated $1,596,953,486

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $LLY Congressional Stock Trading

    Members of Congress have traded $LLY stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.

    Here’s a breakdown of recent trading of $LLY stock by members of Congress over the last 6 months:

    • REPRESENTATIVE DAN NEWHOUSE sold up to $15,000 on 07/10.
    • REPRESENTATIVE MICHAEL A. RULLI sold up to $15,000 on 07/01.
    • REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $115,000 on 06/10, 04/14 and 0 sales.
    • REPRESENTATIVE LIZZIE FLETCHER sold up to $15,000 on 04/08.

    To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

    $LLY Price Targets

    Multiple analysts have issued price targets for $LLY recently. We have seen 11 analysts offer price targets for $LLY in the last 6 months, with a median target of $1350.0.

    Here are some recent targets:

    • Trung Huynh from RBC Capital set a target price of $1500.0 on 07/08/2026
    • Robyn Karnauskas from Truist Securities set a target price of $1370.0 on 07/08/2026
    • Terence Flynn from Morgan Stanley set a target price of $1347.0 on 07/08/2026
    • Chris Schott from JP Morgan set a target price of $1400.0 on 07/07/2026
    • Carter Gould from Cantor Fitzgerald set a target price of $1350.0 on 07/06/2026
    • David Risinger from Leerink Partners set a target price of $1232.0 on 06/25/2026
    • Akash Tewari from Jefferies set a target price of $1350.0 on 06/09/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.